Enlivex Highlights Allocetra’s Impact on Osteoarthritis Treatment
Enlivex Therapeutics Showcases Allocetra's Unique Benefits
Innovative presentations highlight Allocetra™’s mechanism in treating joint diseases.
Ness-Ziona, Israel — Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a pioneering company in macrophage reprogramming immunotherapy, has exciting news. They are set to present findings at the prestigious Osteoarthritis Research Society International (OARSI) 2025 World Congress. This event will occur over several days, offering a platform for leaders in osteoarthritis research to explore new therapeutic avenues.
According to Dr. Oren Hershkovitz, the CEO of Enlivex, these presentations at OARSI will underscore the accumulating evidence of Allocetra’s™ potential as a groundbreaking treatment for patients suffering from osteoarthritis. This therapy aims to restore macrophage homeostasis, which plays a vital role in managing chronic joint inflammation and promoting healthier cartilage function.
Products like Allocetra™ are especially exciting because they are designed to reprogram macrophages, moving them from an inflammatory state to a state that supports healing. By addressing the immune imbalance, Allocetra™ could pave the way for innovative treatments benefitting millions of patients globally, resulting in improved outcomes and reduced reliance on traditional pain management strategies.
Key Findings and Presentations at OARSI 2025
The research team will share data from both preclinical studies and ongoing clinical trials, showcasing the significance of Allocetra™ in the management of osteoarthritis. The data will reflect not only the efficacy of Allocetra™ in reducing inflammation but also significant patient benefits, including pain relief and improved joint function.
In particular, the company has observed promising results. In Phase I/II clinical trials, patients treated with Allocetra™ experienced marked and sustained reductions in pain levels. More remarkably, many avoided the need for knee replacement surgery, demonstrating the potential of this innovative therapy.
Presentation Details
The spotlight will be on two main poster presentations at the conference:
- Title: Phase I/II Clinical Trial of Allocetra™ Cell Therapy for Knee Osteoarthritis: Initial Evidence of Response to Inflammation Modulation
- Flash Talk Session: Pain Mechanisms and Neuroinflammation in OA
- Date and Time: April 26, 2025 | 11:31 AM KST
- Poster Sessions:
- Friday, April 25 | 4:15 – 5:00 PM KST
- Saturday, April 26 | 4:15 – 5:00 PM KST
Additionally, another engaging presentation will be:
- Title: Biological Activity Characterization of Allocetra™, a Novel Macrophage Reprogramming Cell Therapy, in Osteoarthritis Preclinical Models
- Poster Sessions:
- Friday, April 25 | 3:30 – 4:15 PM KST
- Saturday, April 26 | 3:30 – 4:15 PM KST
Meet the Team at OARSI
Dr. Oren Hershkovitz and Einat Galamidi, MD, CMO, will be present and available throughout the congress to engage with attendees and discuss these groundbreaking findings.
About Enlivex Therapeutics
Enlivex is dedicated to transforming the landscape of immune therapies. Their developed product, Allocetra™, represents a step forward in cell therapy. This off-the-shelf solution aims to recalibrate macrophage function, critical for combating various debilitating conditions and enhancing quality of life for patients worldwide.
This pioneering approach, focusing on macrophage reprogramming, opens doors for treatments that could change the paradigm for managing chronic diseases. As research continues to unfold, Enlivex promises to stay at the forefront, seeking to address the underlying causes of immune disorders through innovative therapies.
Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
ENLV@redchip.com
Frequently Asked Questions
What is Allocetra™?
Allocetra™ is an off-the-shelf cell therapy developed by Enlivex, focusing on reprogramming macrophages to restore immune balance.
What are the potential benefits of Allocetra™ therapy?
This therapy aims to reduce chronic inflammation, alleviate pain, and improve joint function in osteoarthritis patients.
Who will present the findings at OARSI 2025?
Dr. Oren Hershkovitz and Einat Galamidi, MD, will present the findings at the congress.
When and where will the OARSI congress take place?
The OARSI 2025 World Congress will happen from April 24-27, in Incheon (Seoul), South Korea.
How can interested parties learn more about Enlivex?
More information about Enlivex and their therapies can be found on their official website at www.enlivex.com.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.